Nexavar in combination with carboplatin and paclitaxel is contraindicated in patients with squamous cell lung cancer. Cardiac ischemia and/or myocardial infarction may occur. Temporary or permanent discontinuation of Nexavar should be considered in patients who develop cardiac ischemia and/or myocardial infarction. An increased risk of bleeding may occur following Nexavar administration. If bleeding necessitates medical intervention, consider permanent discontinuation of Nexavar. continue reading below »
The BCLC Treatment Strategy includes Nexavar for advanced-stage HCC—defined as disease with vascular invasion or metastases. Systemic therapy is the recommended course of treatment by the BCLC at this stage of HCC. Nexavar is the only systemic therapy proven to offer a survival advantage in patients with unresectable HCC.1,2Reprinted with permission from Bruix and Sherman (2010). bili=total bilirubin; CP=Child-Pugh class;
References: 1. Llovet JM, DiBisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100(10):698-711. 2. Llovet JM, Ricci S, Mazzaferro V, et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378-390. 3. Bruix J, Sherman M. Management of Hepatocellular Carcinoma: An Update. Alexandria, VA: American Association for the Study of Liver Diseases. http://www.aasld.org/practiceguidelines 2011. 4. O'Neil BH, Venook AP. Hepatocellular carcinoma: the role of the North American GI Steering Committee Hepatobiliary Task Force and the advent of effective drug therapy. Oncologist. 2007;12(12):1425-1432.